Core Viewpoint - The China Securities Service Industry Index has shown a slight increase over the past month but has declined year-to-date, indicating mixed performance in the service sector [2][3]. Group 1: Index Performance - The China Securities Service Industry Index rose by 1.95% over the past month, decreased by 0.07% over the last three months, and has fallen by 0.89% year-to-date [2]. - The index is designed to reflect the overall performance of listed companies in the service industry, covering sectors such as agriculture, electricity, transportation, finance, real estate, culture, sports, and entertainment [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Changjiang Electric Power (5.94%) - Beijing-Shanghai High-Speed Railway (2.79%) - WuXi AppTec (2.6%) - Ping An Insurance (2.03%) - China State Construction (1.91%) - China Merchants Bank (1.9%) - SF Holding (1.86%) - COSCO Shipping Holdings (1.67%) - Cambricon Technologies (1.63%) - China Telecom (1.61%) [2]. Group 3: Market and Sector Breakdown - The index's holdings are primarily listed on the Shanghai Stock Exchange (75.92%) and the Shenzhen Stock Exchange (24.08%) [3]. - Sector allocations within the index include: - Industrial (26.26%) - Financial (20.63%) - Public Utilities (15.92%) - Information Technology (11.42%) - Communication Services (10.16%) - Healthcare (7.14%) - Real Estate (4.46%) - Consumer Discretionary (2.88%) - Energy (1.14%) [3]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [3].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年6月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 2. 股份分類 | 普通股 | 股份類別 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 | | 否 | | | 證券代號 (如上市) | | 說明 | | 於上海證券交易所上市 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-039 无锡药明康德新药开发股份有限公司 关于 2025 年第二次以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/9 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 4 7 8 | 9 | 日~2025 | 年 | 日 | | 预计回购金额 | 10亿元~10亿元 | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | √为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 6,682,849股 | | | | | | 累计已回购股数占总股本比例 | 0.2314% | | | | | | 累计已回购金额 | 400,038,559.88元 | | | | | | 实际回购价 ...

Group 1 - The core viewpoint of the article highlights the performance and valuation of WuXi AppTec, with a closing price of 63.51 yuan and a rolling PE ratio of 16.41 times, significantly lower than the industry average of 39.82 times [1][2] - As of the first quarter of 2025, a total of 387 institutions hold shares in WuXi AppTec, with 378 being funds, totaling 110,979.98 million shares and a market value of 74.712 billion yuan [1] - The company reported a revenue of 9.655 billion yuan for the first quarter of 2025, representing a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, up 89.06% year-on-year, with a gross margin of 42.26% [1] Group 2 - WuXi AppTec's main business is providing integrated, end-to-end drug research and development services for the global pharmaceutical and life sciences industry, with key products in chemical, testing, and biological services [1] - In terms of market valuation, WuXi AppTec ranks 17th in the medical services industry, which has an average PE ratio of 39.82 times and a median of 46.56 times [1][2] - The company's total market capitalization stands at 183.416 billion yuan [1][2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年5月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | ...

呈交日期： 2025年5月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | | 佔有關事件前的現有已發 | | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | | 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | | ...

Group 1 - The innovative pharmaceutical ETF (560900) has seen a 2.20% increase as of May 29, 2025, with significant trading volume [1] - The CSI Innovative Pharmaceutical Industry Index (931152) rose by 2.32%, with notable gains from constituent stocks such as Zhixiang Jintai (688443) up 8.91%, Sangfor Technologies (688336) up 7.41%, and Maiwei Biotech (688062) up 5.78% [1] - Over the past two weeks, the innovative pharmaceutical ETF (560900) has accumulated a 3.94% increase, ranking it among the top comparable funds [2] Group 2 - CITIC Securities believes that leading innovative pharmaceutical companies have entered a profit phase, with potential for nonlinear profit explosions as commercialization expands [2] - The investment opportunities in the innovative pharmaceutical sector are linked to the clinical progress of molecules under research and the entire commercialization phase, which can last up to ten years [2] - The innovative pharmaceutical ETF closely tracks the CSI Innovative Pharmaceutical Industry Index, which selects no more than 50 representative listed companies involved in innovative drug research and development [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to help investors capitalize on quality technology companies amid a new wave of AI-driven technological advancements [2] - Various actively managed funds focus on emerging industry trends, including the Morgan Emerging Power Fund and the Morgan Smart Connectivity Fund, which targets opportunities in artificial intelligence [3] - The Morgan Hang Seng Technology ETF (513890) and the Morgan CSI Innovative Pharmaceutical Industry ETF (560900) provide passive investment options for technology and innovative pharmaceutical sectors, respectively [3]

Group 1 - The core viewpoint is that the pharmaceutical industry is expected to experience stable growth driven by innovation, policy optimization, and increasing clinical demand due to aging demographics [3] - The National Biopharmaceutical Index (399441) has shown a strong increase of 1.83%, with key stocks like Kylin Pharmaceutical (002821) rising by 5.51% and Zhaoyan New Drug (603127) by 4.66% [1] - The Biopharmaceutical ETF (159839) has seen a cumulative increase of 1.54% over the past two weeks, indicating positive market sentiment [1] Group 2 - Open Source Securities emphasizes that the pharmaceutical sector will benefit from improved drug procurement policies and a favorable external environment, leading to a recovery in the healthcare industry [3] - Citic Securities notes that the pharmaceutical sector achieved its best market returns in the first half of 2025, driven by policy trends and the maturation of pharmaceutical innovation [3] - The current PEG levels for most growth-oriented pharmaceutical companies are below 1, suggesting potential for performance and valuation recovery [3]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年5月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | ...